Stentys’ successful IPO is a perfect demonstration of Aelios’ unique position to advise ambitious entrepreneurs on all aspects of strategic transactions. Stentys’ IPO is the 5th corporate finance transaction for which Aelios advises Stentys and its co-founders.
Stentys’ Chairman, Pr Séguin, had done business in the past with Thibaut de Monclin, a founding partner of Aelios. The relationship intensified when Alain Lostis, another founding partner of Aelios, worked with Pr Séguin on his previous and very successful venture, CoreValve (acquired by Medtronic in 2009 for $700 million in cash): raising capital and advising him on many aspects of relationship with potential corporate buyers.
For his next venture, Stentys, Pr Séguin and co-founder and CEO Gonzague Issenmann, appointed Aelios from the very start to raise their first round of financing subscribed by Sofinnova. Since this first transaction, Aelios and Stentys have built an intense relationship that ranges from reviewing strategic matters to advising on all corporate finance aspects. In the middle of 2010, raising capital through an IPO had become an obvious route to explore for Stentys and Aelios proposed to partner with Allegra to advice on all aspects of the IPO. Allegra brought its technical expertise on the IPO process and Aelios focused on working with the management and the board to build the equity story, ensuring that it is clearly articulated, accurate and backed by solid strategic insight and overlooking all major decision for the entire process.
“As always, it has been a pleasure to work with Aelios, a corporate finance advisor that is consistently giving honest and insightful advices and helps us execute it. This is so rare in this business” comments Pr Jacques Séguin, Chairman of Stentys.
Gonzague Issenmann, CEO of Stentys adds “From strategic matters to detailed tactics in executing corporate finance transactions, Aelios is always there with us in the critical moments”
“We are blessed to have worked one more time with Jacques Séguin and his team and his investors: great inventors, great investors, great entrepreneurs all dedicated to the progress of medicine. We look forward to continuing to serve them and improve patient care” comments Alain Lostis from Aelios “we are also pleased that this successful IPO opens a virtuous cycle in the financing of innovative companies with financial markets working alongside venture funds to create great French companies”.
